<DOC>
	<DOCNO>NCT00027040</DOCNO>
	<brief_summary>The purpose study compare picture brain HIV-infected people memory problem treatment selegiline . Selegiline study drug receive A5090 . HIV patient generally develop memory problem late disease . This examine use noninvasive proton magnetic resonance spectroscopy ( 1H-MRS ) . The effect drug selegiline memory problem also examine .</brief_summary>
	<brief_title>A Study Decreased Mental Function Associated With HIV</brief_title>
	<detailed_description>HIV-associated cognitive impairment generally develop late stage disease . This study propose non-invasively examine pattern extent cerebral injury associate HIV infection response selegiline use 1H-MRS . The following hypothesis test : selegiline , compound antioxidant anti-apoptotic property , reverse metabolic abnormality measure 1H-MRS , change parallel degree improvement cognitive functional performance . This substudy ACTG A5090 . The pattern extent cerebral injury associate HIV infection response selegiline examine use 1H-MRS. 1H-MRS evaluation perform screen Week 24 ( time premature discontinuation ) Step 1 A5090 . The screen MRS exam may perform A5090 screen evaluation ( include lumbar puncture ) complete determined patient eligible A5090 study entry . The screening MRS must perform prior A5090 study drug administration . The Week-24 MRS must perform patient still blind study drug .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Selegiline</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are enrol ACTG protocol A5090 . Meet inclusion/exclusion criterion set forth Step 1 phase AACTG protocol A5090 . Exclusion Criteria Patients eligible study : Claustrophobia ( unless sedation lorazepam zolpidem allow safe performance MRS ) . Metallic implants/medical device ( e.g. , skull implant cardiac device ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>AIDS Dementia Complex</keyword>
	<keyword>Selegiline</keyword>
	<keyword>Oxidative Stress</keyword>
	<keyword>Cognition</keyword>
	<keyword>Neuroprotective Agents</keyword>
	<keyword>Brain Injuries</keyword>
	<keyword>Magnetic Resonance Spectroscopy</keyword>
	<keyword>Protons</keyword>
</DOC>